EU/3/16/1712
Table of contents
About
On 29 August 2016, orphan designation (EU/3/16/1712) was granted by the European Commission to Galapagos NV, Belgium, for 2-((2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)-piperazin-1-yl)-8-methylimidazo[1,2-alpha]pyridin-3-yl)-(methyl)amino)-4-(4-fluorophenyl)-thiazole-5-carbonitrile for the treatment of idiopathic pulmonary fibrosis.
Key facts
Active substance |
2-((2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)-piperazin-1-yl)-8-methylimidazo[1,2-alpha]pyridin-3-yl)-(methyl)amino)-4-(4-fluorophenyl)-thiazole-5-carbonitrile
|
Disease / condition |
Treatment of idiopathic pulmonary fibrosis
|
Date of first decision |
29/08/2016
|
Outcome |
Positive
|
EU designation number |
EU/3/16/1712
|
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Sponsor's contact details
Galapagos N.V.
Generaal De Wittelaan L11 A3
2800 Mechelen Antwerp
Belgium
Tel. +32 1534 2900
E-mail: medicalinfo@glpg.com
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.